Towards a vaccine for Cryptococcus neoformans:: principles and caveats

被引:41
作者
Datta, Kausik
Pirofski, Liise-anne
机构
[1] Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA
[2] Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA
关键词
Cryptococcus neoformans; antibody-mediated immunity; vaccine;
D O I
10.1111/j.1567-1364.2006.00073.x
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
In the Damage-response framework of microbial pathogenesis, infectious diseases are one outcome of a host-microorganism interaction in a susceptible host. In cryptococcal disease, damage to the host is caused by Cryptococcus neoformans virulence determinants, the nature of the host response, or both. Further, the disease may be acute or reactivated from a latent state. Hence, a vaccine for C. neoformans would need to prevent disease resulting from either acute or reactivated infection. The evidence to support the development of a vaccine for C. neoformans that induces antibody-mediated immunity is discussed herein.
引用
收藏
页码:525 / 536
页数:12
相关论文
共 73 条
[31]   GENETIC-CONTROL OF THE HUMORAL RESPONSE TO CRYPTOCOCCAL CAPSULAR POLYSACCHARIDE IN MICE [J].
DROMER, F ;
YENI, P ;
CHARREIRE, J .
IMMUNOGENETICS, 1988, 28 (06) :417-424
[32]   CRYPTOCOCCUS NEOFORMANS ANTIBODY-LEVELS IN PATIENTS WITH AIDS [J].
DROMER, F ;
AUCOUTURIER, P ;
CLAUVEL, JP ;
SAIMOT, G ;
YENI, P .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1988, 20 (03) :283-285
[33]   Quantitative and qualitative differences in the serum antibody profiles of human immunodeficiency virus-infected persons with and without Cryptococcus neoformans meningitis [J].
Fleuridor, R ;
Lyles, RH ;
Pirofski, L .
JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (05) :1526-1535
[34]   A human IgM monoclonal antibody prolongs survival of mice with lethal cryptococcosis [J].
Fleuridor, R ;
Zhong, ZJ ;
Pirofski, LA .
JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (04) :1213-1216
[35]   A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection [J].
Fleuridor, R ;
Lees, A ;
Pirofski, LA .
JOURNAL OF IMMUNOLOGY, 2001, 166 (02) :1087-1096
[36]   Epidemiological evidence for dormant Cryptococcus neoformans infection [J].
Garcia-Hermoso, D ;
Janbon, G ;
Dromer, F .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (10) :3204-3209
[37]   Serologic evidence for Cryptococcus neoformans infection in early childhood [J].
Goldman, DL ;
Khine, H ;
Abadi, J ;
Lindenberg, DJ ;
Pirofski, L ;
Niang, R ;
Casadevall, A .
PEDIATRICS, 2001, 107 (05) :E66
[38]   Exploring the basis of peptide-carbohydrate crossreactivity: Evidence for discrimination by peptides between closely related anti-carbohydrate antibodies [J].
Harris, SL ;
Craig, L ;
Mehroke, JS ;
Rashed, M ;
Zwick, MB ;
Kenar, K ;
Toone, EJ ;
Greenspan, N ;
Auzanneau, FI ;
MarinoAlbernas, JR ;
Pinto, BM ;
Scott, JK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (06) :2454-2459
[39]   OCCURRENCES, IMMUNOGLOBULIN CLASSES, AND BIOLOGICAL-ACTIVITIES OF ANTIBODIES IN NORMAL HUMAN SERUM THAT ARE REACTIVE WITH CRYPTOCCUS NEOFORMANS GLUCURONOXYLOMANNAN [J].
HOUPT, DC ;
PFROMMER, GST ;
YOUNG, BJ ;
LARSON, TA ;
KOZEL, TR .
INFECTION AND IMMUNITY, 1994, 62 (07) :2857-2864
[40]   Immune reconstitution cryptococcosis after initiation of successful highly active antiretroviral therapy [J].
Jenny-Avital, ER ;
Abadi, M .
CLINICAL INFECTIOUS DISEASES, 2002, 35 (12) :E128-E133